In hindsight the biggest mistake was probably running the two covid trials concurrently, especially when the CD10 was obviously going to be so underpowered.

With the limited resources of a small pharma, everything should have been focused on the CD12. Instead, enrollment lagged and we wound up with the frantic push during the later part of last year to get it finished. If management had been concentrating on just the CD12, maybe we could have gotten results a couple of months ago and now would be a lot closer to getting the results of the final 140 patients.